Go Pro

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck & Co., Inc..

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,174.17 -10.46 (-0.88%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • Eli Lilly and Co recently secured FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, which offers a more convenient alternative to daily injections and strengthens the company's position in the diabetes care market.
  • The company demonstrated strong financial performance in its most recent earnings report, with actual revenue of $22.97 billion significantly exceeding the consensus estimate of $20.82 billion, indicating robust demand for its pharmaceutical products.
  • Analysts maintain a Moderate Buy consensus rating with a price target of $1,304.86, suggesting that the current stock price of $1,184.38 offers potential upside as the market continues to value the company's growth in obesity and diabetes treatments.

Cons of Eli Lilly and Company

  • Despite strong growth, Eli Lilly and Co faces intensifying competition in the GLP-1 market, with rivals like Novo Nordisk actively pursuing strategies to regain market share, which could pressure pricing and volume growth for the company's obesity and diabetes drugs.
  • The company's valuation remains high with a P/E ratio of 39.74, which may limit upside potential if growth rates slow or if the market becomes more sensitive to pricing pressures in the pharmaceutical sector.
  • Recent insider activity shows selling pressure, with executives such as Patrik Jonsson and Anat Hakim selling shares in August 2026, which some investors may interpret as a signal of limited near-term upside or personal financial needs rather than confidence in future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.11 trillion
P/E Ratio
39.40
Consensus Rating
Moderate Buy
Consensus Price Target
$1,311.96 (+11.7% Upside)
Volume
1.54 million shares
Average Volume
2.99 million shares
Today's Range
$1,173.01
▼
$1,215.00
50-Day Range
$1,115.53
▼
$1,280.62
52-Week Range
$763.30
▼
$1,292.65
Dividend Yield
0.58%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$266.88 -0.69 (-0.26%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson recently demonstrated significant clinical success in its oncology franchise, with new data showing that a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early-line relapsed or refractory multiple myeloma, supporting the long-term growth potential of its cancer therapies.
  • The company's neuroscience portfolio is expanding rapidly following the acquisition of Intra-Cellular Therapies, as CAPLYTA delivered statistically significant and rapid symptom improvement in a Phase 3 study for bipolar I mania, potentially broadening its revenue base beyond schizophrenia and bipolar depression.
  • Johnson & Johnson is strengthening its immunology pipeline with the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and positive Phase 4 results for TREMFYA in axial psoriatic arthritis, providing a potential successor to declining STELARA sales and addressing a high-growth therapeutic area.

Cons of Johnson & Johnson

  • At a P/E ratio of 31.54, Johnson & Johnson trades at a premium valuation that leaves less room for disappointment, as analysts note that the stock has substantially outperformed peers despite slower revenue growth, making investors more sensitive to any execution risks or product slowdowns.
  • The company faces ongoing pressure from the erosion of its blockbuster drug STELARA, which is declining in sales, creating a significant challenge for the company to replace this revenue stream with newer products like ICOTYDE and TREMFYA in a timely manner.
  • Recent insider activity shows a trend of selling, with executives such as Timothy Schmid and Elizabeth Forminard selling significant portions of their holdings in the last few months, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$643.15 billion
P/E Ratio
30.92
Consensus Rating
Moderate Buy
Consensus Price Target
$275.87 (+3.4% Upside)
Volume
1.69 million shares
Average Volume
7.95 million shares
Today's Range
$265.96
▼
$268.48
50-Day Range
$254.54
▼
$278.66
52-Week Range
$182.94
▼
$281.07
Dividend Yield
1.97%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$263.48 +0.19 (+0.07%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently received FDA approval for Juvmo (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, a significant milestone from its Cerevel acquisition that expands its neuroscience portfolio and offers a differentiated treatment option for a large patient population.
  • The company demonstrated strong financial performance in the second quarter of 2026, reporting revenue of $16.99 billion, which exceeded the consensus estimate of $16.80 billion and represented a 10.2% year-over-year increase, indicating robust demand for its core products.
  • AbbVie's earnings per share for the second quarter of 2026 was $3.65, beating the analyst consensus of $3.61, and the company has guided for third-quarter 2026 EPS between $3.84 and $3.88, suggesting continued profitability and operational strength.

Cons of AbbVie

  • AbbVie's valuation is elevated, with a price-to-earnings ratio of 75.25, which is significantly higher than many peers in the biotechnology sector, potentially limiting upside potential if earnings growth does not accelerate to justify the premium.
  • The company's payout ratio for dividends is 195.48%, meaning it is paying out more in dividends than it is earning in net income, which could raise concerns about the sustainability of the dividend if profitability does not improve.
  • Recent insider activity includes significant share sales, such as EVP Nicholas Donoghoe selling 32,710 shares in August 2026, which may signal that company executives are taking advantage of the high stock price to reduce their personal holdings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$465.52 billion
P/E Ratio
74.43
Consensus Rating
Moderate Buy
Consensus Price Target
$272.66 (+3.5% Upside)
Volume
1.03 million shares
Average Volume
6.44 million shares
Today's Range
$262.89
▼
$265.36
50-Day Range
$243.64
▼
$266.39
52-Week Range
$190.75
▼
$269.39
Dividend Yield
2.60%
Merck & Co., Inc. stock logo

4. Merck & Co., Inc. NYSE:MRK

$146.96 -2.32 (-1.56%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck recently secured a significant pipeline expansion by signing a $2.13 billion exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor, which adds a promising new asset to its oncology portfolio.
  • The FDA approved a label expansion for WINREVAIR to include data from the Phase 3 HYPERION trial for adults recently diagnosed with pulmonary arterial hypertension, broadening the commercial opportunity for this therapy and strengthening the company's growth portfolio.
  • Merck's stock is currently trading at $148.74, which is below the consensus price target of $154.24, suggesting potential upside as analysts maintain a Moderate Buy rating based on recent positive catalysts.

Cons of Merck & Co., Inc.

  • Merck and Daiichi Sankyo voluntarily withdrew their Biologics License Application for accelerated approval of ifinatamab deruxtecan for extensive-stage small cell lung cancer after the FDA indicated that current data would not support clearance, representing a setback for a key pipeline asset.
  • The company's payout ratio is currently 272.00%, meaning it is paying out more in dividends than it is earning in net income, which may raise concerns about the sustainability of the 2.29% dividend yield given the recent negative EPS of $0.13 in the latest quarter.
  • Merck's price-to-earnings ratio stands at 118.99, a valuation level that is significantly elevated and may leave little room for error if future earnings growth does not materialize to justify the premium price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$362.57 billion
P/E Ratio
117.57
Consensus Rating
Moderate Buy
Consensus Price Target
$145.76 (-0.8% Downside)
Volume
3.87 million shares
Average Volume
10.70 million shares
Today's Range
$146.22
▼
$149.27
50-Day Range
$127.61
▼
$156.54
52-Week Range
$82.01
▼
$156.92
Dividend Yield
2.29%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$368.87 -6.07 (-1.62%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group demonstrated strong earnings momentum in the second quarter of 2026, reporting earnings per share of $6.38, which significantly exceeded the analyst consensus estimate of $4.94, indicating that the company's operational improvements are translating into tangible financial results for shareholders.
  • Management has raised its full-year 2026 adjusted earnings per share guidance to a range of $19.50 to $20.00, a substantial increase from previous estimates, which signals confidence in the company's ability to sustain margin expansion and profitability growth throughout the remainder of the fiscal year.
  • The stock is currently trading at $377.02, which is well below the consensus analyst price target of $456.56, suggesting that the market may be undervaluing the company's recent turnaround and potential for further upside as it continues to execute its strategic initiatives.

Cons of UnitedHealth Group

  • Revenue growth has nearly stalled, with second-quarter 2026 revenue of $112.03 billion showing only a 0.4% increase compared to the same period last year, raising concerns about the company's ability to drive top-line growth while relying heavily on cost controls to boost earnings.
  • The commercial segment's cost trend ran modestly above 11% in the first half of 2026, with issues related to arbitration abuse and provider coding intensity squeezing margins, a problem that management has pushed the recovery timeline for past 2027, indicating prolonged pressure on profitability.
  • CEO Patrick Conway has engaged in multiple stock sales in 2026, including a recent transaction on August 21, 2026, where he sold 1,169 shares at an average price of $390.00, which some investors may interpret as a signal of reduced insider confidence or a desire to diversify personal holdings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$331.10 billion
P/E Ratio
23.74
Consensus Rating
Moderate Buy
Consensus Price Target
$465.75 (+26.3% Upside)
Volume
2.02 million shares
Average Volume
7.41 million shares
Today's Range
$365.72
▼
$374.93
50-Day Range
$370.76
▼
$431.68
52-Week Range
$255.96
▼
$461.62
Dividend Yield
2.46%
Novartis stock logo

6. Novartis NYSE:NVS

$143.74 -1.98 (-1.36%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG shares are currently trading at $146.95, which is below the consensus price target of $153.00, suggesting potential for capital appreciation as the stock recovers from its recent gap down to $139.49 in early September.
  • Analysts at Zacks Research and Erste Group Bank recently raised their full-year 2027 earnings per share estimates, with Zacks now projecting $9.75 per share and Erste Group forecasting $9.81 per share, indicating strong confidence in the company's future profitability despite recent challenges.
  • The company received a positive opinion from the European Committee for Medicinal Products for Human Use for Cosentyx for polymyalgia rheumatica, which expands the therapeutic reach of this key immunology franchise and supports long-term revenue growth.

Cons of Novartis

  • Novartis AG paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in September 2026 after three patient deaths from a severe immune reaction, representing a significant setback for its neuroscience and immunology pipeline.
  • The company discontinued development of its ALS drug lifonebart after it failed to meet primary and secondary endpoints in a Phase II trial, highlighting the risks associated with its neuroscience portfolio and potential loss of investment in that area.
  • State Street Corp reduced its stake in Novartis AG by 96.3% in the second quarter, selling over 1.3 million shares, which may signal a lack of confidence from major institutional investors in the company's near-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$274.27 billion
P/E Ratio
21.68
Consensus Rating
Hold
Consensus Price Target
$148.40 (+3.2% Upside)
Volume
2.05 million shares
Average Volume
2.00 million shares
Today's Range
$143.67
▼
$145.50
50-Day Range
$137.22
▼
$163.27
52-Week Range
$121.57
▼
$170.46
Dividend Yield
2.12%
Thermo Fisher Scientific stock logo

7. Thermo Fisher Scientific NYSE:TMO

$681.77 +2.16 (+0.32%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. recently reported strong second-quarter results on July 23, 2026, beating analyst expectations with earnings per share of $6.03 compared to the consensus estimate of $5.71, while revenue of $11.99 billion also exceeded the $11.71 billion forecast, demonstrating robust operational performance and demand for its life sciences solutions.
  • The company has established a dominant position in high-growth sectors such as gene-transfer technologies and bioreactors, which are projected to expand significantly through 2035 and 2036, providing a long-term tailwind for its instruments, reagents, and manufacturing solutions as gene and cell therapies advance.
  • Thermo Fisher Scientific Inc. is actively expanding its product portfolio with recent launches like the Gibco CHO-K1 Catalog Panel, a cGMP-ready media offering for biologics developers, which enhances its value proposition for scalable cell culture performance and productivity in the biopharmaceutical market.

Cons of Thermo Fisher Scientific

  • Despite the strong recent performance, the current stock price of $677.71 is significantly higher than the average analyst price target of $624.64, suggesting that the stock may be overvalued relative to Wall Street's consensus fair value estimate.
  • Company insiders have engaged in substantial selling activity recently, with CEO Marc Casper and other executives selling tens of thousands of shares in August 2026, which can signal a lack of confidence in the stock's short-term upside or a desire to diversify personal holdings.
  • The company's P/E ratio stands at 36.46, which is relatively high compared to many industrial and healthcare peers, indicating that investors are paying a premium for growth that may not be immediately reflected in current earnings, increasing the risk if growth slows.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$252.09 billion
P/E Ratio
36.67
Consensus Rating
Moderate Buy
Consensus Price Target
$628.78 (-7.8% Downside)
Volume
901,628 shares
Average Volume
2.25 million shares
Today's Range
$671.63
▼
$683.63
50-Day Range
$526.19
▼
$681.04
52-Week Range
$435.27
▼
$683.63
Dividend Yield
0.28%
Astrazeneca stock logo

8. Astrazeneca NYSE:AZN

$162.50 -1.71 (-1.04%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$252.02 billion
P/E Ratio
24.29
Consensus Rating
Moderate Buy
Consensus Price Target
$206.67 (+27.2% Upside)
Volume
1.32 million shares
Average Volume
2.80 million shares
Today's Range
$162.63
▼
$164.48
50-Day Range
$155.79
▼
$173.24
52-Week Range
$153.41
▼
$212.71
Dividend Yield
2.61%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$423.76 +0.12 (+0.03%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful improvements in disease activity sustained through Week 48 with mostly mild-to-moderate side effects, which strengthens the company's pipeline and future growth expectations in an area with no approved disease-modifying therapies.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $6.29, which beat analysts' consensus estimates of $5.62 by $0.67, alongside revenue of $10.05 billion that exceeded the $9.43 billion estimate, indicating robust operational execution and demand for its therapeutics.
  • Amgen Inc. offers a compelling income stream with a dividend yield of 2.48% based on the current stock price of $418.13, supported by a recent quarterly dividend payment of $2.52 per share, which provides a steady return for income-focused investors despite the company's growth profile.

Cons of Amgen

  • The current consensus rating from Wall Street analysts is "Hold" with a consensus price target of $381.32, which is below the current stock price of $418.13, suggesting that the stock may be overvalued relative to the average analyst expectation and offering limited upside potential for new buyers.
  • Insider selling activity has been notable recently, with senior executives such as SVP Nancy Grygiel and SVP Rachna Khosla selling a combined total of over 6,000 shares in August 2026, which can signal a lack of confidence from company leadership or a desire to diversify personal holdings at current price levels.
  • Amgen Inc. carries a high debt-to-equity ratio of 4.44, indicating a significant level of leverage relative to its equity base, which could increase financial risk and limit the company's flexibility in managing cash flows or responding to economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.98 billion
P/E Ratio
26.32
Consensus Rating
Hold
Consensus Price Target
$385.25 (-9.1% Downside)
Volume
826,284 shares
Average Volume
2.75 million shares
Today's Range
$421.19
▼
$426.59
50-Day Range
$366.05
▼
$444.12
52-Week Range
$283.00
▼
$447.03
Dividend Yield
2.41%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$150.57 -0.71 (-0.47%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. recently expanded the scope of its royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis, a move that aims to accelerate manufacturing readiness and technology transfer in 120 high-incidence, lower-income countries while supporting the ongoing Phase 3 PURPOSE 365 study.
  • The company has demonstrated strong revenue momentum, with the most recent quarter showing revenue of $7.80 billion, which exceeded analyst estimates of $7.40 billion and represented a 10.6% increase compared to the same quarter last year, driven by double-digit expansion in its HIV business.
  • Investors can benefit from a consistent income stream as the company recently raised its quarterly dividend by 3.8% to $0.82 per share, resulting in an annualized dividend of $3.28 and a yield of approximately 2.2% based on the current stock price of $151.28.

Cons of Gilead Sciences

  • The company reported a negative net margin of 10.64% and a negative return on equity of 2.11% in the most recent quarter, with earnings per share of ($6.75) indicating that the firm is currently operating at a loss despite beating consensus estimates, which may signal underlying profitability challenges.
  • Insider selling activity has been notable, with CEO Daniel O'Day and CFO Andrew D. Dickinson both executing sales of shares in September 2026 under pre-arranged trading plans, a trend that can sometimes indicate a lack of confidence in the stock's near-term upside from those closest to the company's operations.
  • Gilead Sciences, Inc. carries a high debt-to-equity ratio of 2.03, which suggests a significant level of leverage that could constrain financial flexibility or increase risk during periods of economic uncertainty or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$186.79 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$158.78 (+5.5% Upside)
Volume
1.45 million shares
Average Volume
6.88 million shares
Today's Range
$149.08
▼
$151.28
50-Day Range
$129.31
▼
$152.67
52-Week Range
$108.46
▼
$157.29
Dividend Yield
2.15%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$99.56 -1.39 (-1.38%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories recently demonstrated strong financial performance by beating consensus estimates in its most recent quarterly report, posting earnings per share of $1.31 against an expected $1.28 and generating revenue of $12.59 billion, which represented a 13.0% year-over-year increase. This ability to consistently exceed analyst expectations and drive double-digit revenue growth signals robust operational execution and demand for its diversified healthcare products, providing a solid foundation for future earnings stability.
  • The company has secured a significant strategic partnership with Berry Street that combines Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered registered-dietitian and nutrition-coaching platform. This collaboration is expected to improve the adoption of the Lingo device, expand Abbott’s consumer health ecosystem, and strengthen its competitive position in the rapidly growing metabolic-health services market, creating a new revenue stream that leverages its existing technology.
  • Abbott Laboratories offers a compelling income opportunity with a current dividend yield of 2.49%, based on a quarterly dividend of $0.63 per share. For investors seeking steady cash flow, this yield is supported by the company’s strong financial position, including a debt-to-equity ratio of 0.57 and a current ratio of 1.38, which indicates the company has sufficient liquidity to maintain and potentially grow its dividend payments over time.

Cons of Abbott Laboratories

  • Abbott Laboratories agreed to pay approximately $385 million to settle infant-formula litigation, which represents a significant cash outflow that will impact near-term financial results. Beyond the direct cost, this settlement creates a reputational overhang that may weigh on investor sentiment and could lead to increased regulatory scrutiny or legal risks in the future, potentially distracting management from strategic growth initiatives.
  • The stock is currently trading at a price-to-earnings ratio of 32.69, which is relatively high compared to many other healthcare companies and may limit the upside potential for value-oriented investors. This valuation suggests that the market has already priced in significant future growth, meaning that any disappointment in earnings or revenue growth could lead to a sharp decline in the stock price, as seen when the stock fell from its 52-week high of $135.45 to its current level of $101.01.
  • Recent institutional investor activity has been mixed, with several major funds reducing their positions in the stock during the second quarter. For example, QRG Capital Management Inc. sold 83,416 shares, a 28.7% decrease in its stake, and Envestnet Asset Management Inc. trimmed its position by 23.7%. This trend of institutional selling may indicate a lack of confidence in the stock's short-term performance or a shift in portfolio allocation away from Abbott Laboratories.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$172.28 billion
P/E Ratio
32.22
Consensus Rating
Moderate Buy
Consensus Price Target
$119.50 (+20.0% Upside)
Volume
2.23 million shares
Average Volume
11.36 million shares
Today's Range
$99.13
▼
$100.63
50-Day Range
$100.69
▼
$116.70
52-Week Range
$81.97
▼
$135.45
Dividend Yield
2.50%
Novo Nordisk A/S stock logo

12. Novo Nordisk A/S NYSE:NVO

$38.24 -0.08 (-0.20%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Novo Nordisk recently announced a significant strategic expansion by entering an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP dual receptor agonist. This deal, valued at up to $2.6 billion including a $300 million upfront payment, strengthens the company's pipeline in the obesity and diabetes markets by adding a novel oral formulation that could compete with existing injectable therapies and address patient preference for non-invasive treatments.
  • The company demonstrated strong clinical competitiveness with the Phase 3 REIMAGINE 5 trial results for CagriSema, where adults with type 2 diabetes receiving the 1 mg/1 mg dose lost an estimated 12.4% of their body weight after 60 weeks. This result compares favorably with Eli Lilly’s tirzepatide, suggesting that Novo Nordisk’s next-generation asset has the potential to reclaim market share and support a recovery in the company's growth trajectory.
  • Novo Nordisk is actively supporting its share price through a buyback program of up to DKK 15 billion over the next 12 months. Share repurchases reduce the number of shares outstanding, which can increase earnings per share and signal management’s confidence in the company's intrinsic value, particularly given that the stock is currently trading at a depressed valuation relative to its historical highs.

Cons of Novo Nordisk A/S

  • Novo Nordisk faces intensifying competition in the GLP-1 market, with Eli Lilly continuing to pull ahead in the U.S. market and Roche reporting mid-stage data for its experimental enicepatide, which showed 15.5% average weight loss. This broadening competition threatens Novo's market share and pricing power, as rivals offer comparable or superior efficacy, potentially eroding the company's dominant position in obesity and diabetes care.
  • The company recently cut its dividend, reducing the payout from $1.2751 per share to $0.5786 per share, which was paid on August 25, 2026. This negative change in dividend policy may disappoint income-focused investors and could signal that management is prioritizing capital preservation or other strategic investments over shareholder returns, potentially impacting the stock's appeal as a defensive holding.
  • Analyst sentiment remains cautious, with a consensus rating of "Hold" and a recent downgrade from Deutsche Bank Aktiengesellschaft from "hold" to "sell" on August 27, 2026. Additionally, Zacks Research and Weiss Ratings have only recently upgraded their ratings to "hold," indicating that many analysts still see significant risks or lack of near-term catalysts for a strong price appreciation, despite the current low valuation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$170.72 billion
P/E Ratio
9.35
Consensus Rating
Hold
Consensus Price Target
$102.85 (+169.0% Upside)
Volume
15.03 million shares
Average Volume
17.10 million shares
Today's Range
$37.88
▼
$38.77
50-Day Range
$38.19
▼
$51.56
52-Week Range
$35.12
▼
$64.16
Dividend Yield
2.10%
Pfizer stock logo

13. Pfizer NYSE:PFE

$28.84 +0.12 (+0.40%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. offers a high dividend yield of 6.00%, which is attractive for income-focused investors seeking regular cash flow from their portfolio holdings.
  • The company recently reported strong financial performance, beating consensus estimates with an EPS of $0.77 and revenue of $15.03 billion in the most recent quarter, indicating solid operational execution.
  • Pfizer Inc. is set to present data from 45 oncology research abstracts at the upcoming ESMO Congress, highlighting a robust pipeline and continued investment in cancer treatments.

Cons of Pfizer

  • Analysts have a consensus rating of "Hold" with a price target of $28.39, which is slightly below the current stock price of $28.71, suggesting limited upside potential in the near term.
  • There are concerns about the sustainability of the high dividend yield, as some analyses point to an unfavorable payout ratio that could increase risk if earnings weaken.
  • Pfizer Inc. faces ongoing challenges from declining revenue in its COVID-19 products, which continues to impact overall growth and may limit future earnings expansion.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$164.35 billion
P/E Ratio
37.94
Consensus Rating
Hold
Consensus Price Target
$28.39 (-1.5% Downside)
Volume
14.19 million shares
Average Volume
40.69 million shares
Today's Range
$28.55
▼
$28.95
50-Day Range
$24.53
▼
$29.02
52-Week Range
$23.62
▼
$29.21
Dividend Yield
6.00%
Danaher stock logo

14. Danaher NYSE:DHR

$223.60 -2.51 (-1.11%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Recent analyst sentiment has turned sharply positive, with Goldman Sachs raising its price target from $210.00 to $250.00 and assigning a buy rating, suggesting significant upside potential relative to the current stock price of $226.13.
  • The company demonstrated strong fundamental performance in its most recent earnings report on July 20, 2026, beating consensus estimates with $1.94 in earnings per share and generating $6.26 billion in revenue, which represented a 5.5% year-over-year increase.
  • Management has shown confidence in future growth by raising its full-year 2026 earnings per share guidance to a range of $8.45 to $8.60, which exceeds the current consensus estimate of $8.48 and indicates continued operational momentum.

Cons of Danaher

  • The stock is trading at a premium valuation with a price-to-earnings ratio of 40.16, which is significantly higher than the market average and may limit upside potential if earnings growth slows.
  • Recent institutional activity shows mixed signals, with Engineers Gate Manager LP selling 66,244 shares and reducing its stake by 94.0% during the second quarter, indicating a lack of confidence from some major investors.
  • Short interest has increased in recent months, with shares shorted rising to 8,344,032 as of September 15, 2026, suggesting that a portion of the market is betting on a decline in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.19 billion
P/E Ratio
39.72
Consensus Rating
Moderate Buy
Consensus Price Target
$230.23 (+3.0% Upside)
Volume
1.98 million shares
Average Volume
4.45 million shares
Today's Range
$219.69
▼
$226.11
50-Day Range
$179.12
▼
$227.51
52-Week Range
$160.93
▼
$242.80
Dividend Yield
0.71%
Intuitive Surgical stock logo

15. Intuitive Surgical NASDAQ:ISRG

$408.96 -3.22 (-0.78%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. recently received CE mark approval for using its da Vinci SP single-port robotic system in transvaginal gynecologic procedures, a world's-first indication that broadens its clinically supported use in complex anatomical spaces and deepens its position in minimally invasive, scarless surgery.
  • The company is expanding robotic surgery into ambulatory surgery centers with lower-cost XiR systems, which opens access to new customers and outpatient procedures, creating a new growth engine beyond traditional hospital settings.
  • Intuitive Surgical, Inc. reported strong second-quarter results with revenue of $2.89 billion, beating analyst expectations of $2.83 billion, and earnings per share of $2.80, which exceeded the consensus estimate of $2.48, demonstrating robust demand and operational efficiency.

Cons of Intuitive Surgical

  • Intuitive Surgical, Inc. stock has declined sharply this year, with a 29% drop, underperforming the S&P 500 which returned 16.5% over the same period, reflecting market concerns about moderating U.S. procedure growth and valuation pressures.
  • Several major brokerages have recently lowered their price targets, including Stifel Nicolaus cutting from $670 to $550, Wells Fargo reducing from $654 to $487, and Leerink Partners dropping from $573 to $454, signaling a more cautious outlook on the company's future earnings potential.
  • Insider selling has been notable, with executives such as Gary Loeb and Gary Guthart selling shares in August 2026, and insiders collectively selling 12,370 shares worth approximately $4.89 million in the last ninety days, which may indicate reduced confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.60 billion
P/E Ratio
46.89
Consensus Rating
Moderate Buy
Consensus Price Target
$508.68 (+24.4% Upside)
Volume
661,182 shares
Average Volume
2.44 million shares
Today's Range
$405.51
▼
$410.74
50-Day Range
$332.02
▼
$414.79
52-Week Range
$328.57
▼
$603.88
Dividend Yield
N/A
Vertex Pharmaceuticals stock logo

16. Vertex Pharmaceuticals NASDAQ:VRTX

$526.38 -0.35 (-0.07%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease, a significant expansion beyond its core cystic fibrosis business that has attracted analyst attention and suggests new growth engines in the kidney disease sector.
  • The stock is currently trading at $526.19, which is below the consensus price target of $573.83 from analysts who maintain a Moderate Buy rating, indicating potential upside as the market digests recent clinical successes and pipeline diversification.
  • Vertex Pharmaceuticals Incorporated demonstrated strong financial performance in the most recent quarter with revenue of $3.33 billion, exceeding analyst estimates of $3.23 billion and representing a 12.5% year-over-year increase, highlighting robust commercial execution.

Cons of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated recently missed its earnings per share consensus estimate by $0.01 in the latest quarter, reporting $4.73 against an expected $4.74, which may signal challenges in maintaining consistent profitability growth despite revenue beats.
  • There has been significant insider selling activity, with multiple executives including the CMO and EVPs selling shares in recent months, such as Carmen Bozic selling over 10,000 shares in May and June 2026, which can be interpreted as a lack of confidence in near-term stock appreciation.
  • The company's price-to-earnings ratio stands at 30.63, which is relatively high and may limit upside potential if growth slows, especially given that the stock has already risen significantly from its 52-week low of $379.72 to its current level.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.52 billion
P/E Ratio
30.62
Consensus Rating
Moderate Buy
Consensus Price Target
$575.13 (+9.3% Upside)
Volume
404,173 shares
Average Volume
1.38 million shares
Today's Range
$524.66
▼
$529.72
50-Day Range
$470.72
▼
$557.96
52-Week Range
$392.49
▼
$560.25
Dividend Yield
N/A
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$63.00 +0.14 (+0.22%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • Bristol-Myers Squibb was recently upgraded from a hold to a strong-buy rating by Zacks Research, which also raised its earnings estimates for the company, including full-year 2027 EPS to $6.24 and full-year 2028 EPS to $5.23, signaling improved confidence in the company's future financial performance.
  • The stock currently trades at $62.84, which is below the consensus price target of $67.06, suggesting potential upside for investors as the current price is lower than what analysts on average expect the stock to reach.
  • Bristol-Myers Squibb offers a dividend yield of 4.05%, providing a steady income stream for investors, which is particularly attractive in a market where income-focused strategies are gaining popularity.

Cons of Bristol Myers Squibb

  • Despite recent positive developments, investors remain concerned about patent expirations and declines in established blockbuster products, which could negatively impact the company's revenue and earnings in the long term.
  • The company's debt-to-equity ratio is 1.89, indicating a relatively high level of debt compared to its equity, which could pose financial risks if interest rates rise or if the company faces unexpected expenses.
  • Bristol-Myers Squibb's revenue growth has been modest, with a year-over-year increase of 5.7% in the most recent quarter, which may not be sufficient to offset the impact of declining sales from mature products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$128.69 billion
P/E Ratio
13.88
Consensus Rating
Moderate Buy
Consensus Price Target
$67.06 (+6.4% Upside)
Volume
6.26 million shares
Average Volume
11.95 million shares
Today's Range
$62.87
▼
$64.13
50-Day Range
$60.79
▼
$68.06
52-Week Range
$42.52
▼
$68.64
Dividend Yield
3.94%
Medtronic stock logo

18. Medtronic NYSE:MDT

$86.81 -0.28 (-0.32%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently announced a $700 million strategic partnership with Cornerstone Robotics to distribute the Sentire surgical system alongside its proprietary Hugo robotic-assisted surgery system in Europe, China, and Singapore, positioning the company to capture growth in the rapidly expanding medical robotics market which is projected to grow from $20.6 billion in 2026 to $41.7 billion by 2031.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $1.45 which beat analyst estimates of $1.39, while revenue reached $9.76 billion, exceeding expectations of $9.55 billion and representing a 13.7% year-over-year increase, indicating accelerating growth momentum.
  • Medtronic plc offers a compelling income opportunity with a current dividend yield of 3.25%, supported by a recent quarterly dividend announcement of $0.72 per share payable on October 16th, which provides a steady cash flow for income-focused investors.

Cons of Medtronic

  • Medtronic plc is currently trading at $88.47, which is significantly below its 52-week high of $106.33, reflecting a substantial decline in value over the past year that may indicate ongoing market skepticism about the company's growth trajectory or valuation.
  • Recent institutional activity shows mixed signals, with Envestnet Asset Management Inc. decreasing its holdings by 9.4% in the second quarter and QRG Capital Management Inc. cutting its stake by 6.6%, suggesting that some large investors are reducing their exposure to the stock.
  • The company's payout ratio is currently 70.94%, which is relatively high and may limit the amount of free cash flow available for reinvestment in research and development or debt reduction, potentially constraining long-term growth capabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.04 billion
P/E Ratio
21.38
Consensus Rating
Moderate Buy
Consensus Price Target
$103.92 (+19.7% Upside)
Volume
13.18 million shares
Average Volume
9.10 million shares
Today's Range
$86.20
▼
$87.42
50-Day Range
$82.00
▼
$94.13
52-Week Range
$73.31
▼
$106.33
Dividend Yield
3.22%
CVS Health stock logo

19. CVS Health NYSE:CVS

$85.94 -1.16 (-1.34%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported second-quarter earnings that significantly exceeded market expectations, with actual earnings per share of $2.58 compared to a consensus estimate of $1.87, demonstrating strong operational execution and profitability that supports the stock's current price of $89.16.
  • The company has received a "Moderate Buy" consensus rating from twenty-two research analysts, with an average price target of $107.24, indicating that Wall Street believes the stock is undervalued relative to its fundamental performance and growth potential.
  • CVS Health Co. offers a dividend yield of 3.13%, providing a steady income stream for investors, supported by a payout ratio of 70.37% which suggests the company is managing its cash flow to maintain shareholder returns while investing in its business.

Cons of CVS Health

  • Proposed Medicare restrictions on remote patient monitoring could reduce reimbursement or utilization for CVS Health Co., creating uncertainty about the business's outlook and potentially impacting revenue from its Health Services segment.
  • Insider selling activity has been notable, with Director Larry Robbins selling over 3.3 million shares in May 2026, which may signal a lack of confidence from company insiders in the stock's near-term performance.
  • The company's debt-to-equity ratio of 0.74 and current ratio of 0.87 indicate a moderate level of financial leverage and liquidity constraints, which could limit its flexibility in responding to economic downturns or increased interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$109.91 billion
P/E Ratio
22.73
Consensus Rating
Moderate Buy
Consensus Price Target
$107.24 (+24.8% Upside)
Volume
3.19 million shares
Average Volume
8.24 million shares
Today's Range
$85.42
▼
$87.44
50-Day Range
$84.96
▼
$109.41
52-Week Range
$69.51
▼
$110.68
Dividend Yield
3.03%
Stryker stock logo

20. Stryker NYSE:SYK

$275.37 -3.40 (-1.22%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently reported strong financial performance in its most recent quarter, beating consensus estimates with earnings per share of $3.69 compared to the expected $3.49, while also achieving revenue of $6.59 billion, which exceeded the $6.58 billion forecast and represented a 9.4% year-over-year increase.
  • The company maintains a favorable valuation profile with a current stock price of $272.11, which is significantly below the consensus price target of $380.40, suggesting substantial potential upside for investors as the stock trades at a P/E ratio of 28.20.
  • Stryker Co. offers a stable income stream through its dividend, which has a yield of 1.28% and a payout ratio of 36.48%, indicating that the company retains a significant portion of its earnings for reinvestment while still providing regular cash returns to shareholders.

Cons of Stryker

  • Stryker Co. is facing legal scrutiny, with Pomerantz LLP and Block & Leviton investigating claims on behalf of investors for potential securities law violations, which could lead to significant financial liabilities and reputational damage.
  • The company disclosed persisting peripheral vascular manufacturing issues that were previously thought to be resolved, causing an 8.8% drop in the stock price on September 8, 2026, and raising concerns about operational execution and product quality.
  • Analysts have recently lowered their price targets for Stryker Co., with Raymond James cutting its target from $370 to $330 and Canaccord Genuity Group reducing its target from $400 to $385, reflecting a more cautious outlook on the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$105.62 billion
P/E Ratio
28.54
Consensus Rating
Moderate Buy
Consensus Price Target
$372.64 (+35.3% Upside)
Volume
1.10 million shares
Average Volume
2.44 million shares
Today's Range
$273.05
▼
$279.37
50-Day Range
$269.98
▼
$352.35
52-Week Range
$267.00
▼
$392.55
Dividend Yield
1.28%
McKesson stock logo

21. McKesson NYSE:MCK

$861.53 -3.29 (-0.38%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. recently reported first-quarter fiscal 2027 results where it beat consensus estimates, posting earnings per share of $9.93 against an expected $9.56 and generating revenue of $105.38 billion, which exceeded the $103.88 billion forecast and represented a 7.7% year-over-year increase.
  • The company has strengthened its financial outlook by raising its full-year fiscal 2027 adjusted earnings per share guidance to a range of $44.20 to $45.00, a move that analysts suggest supports the current valuation and indicates confidence in continued operational expansion.
  • Wall Street maintains a positive stance on the stock, with a consensus rating of Moderate Buy and an average price target of $973.44, which implies significant upside potential from the current stock price of $866.56.

Cons of McKesson

  • McKesson Co. is currently navigating a confirmed cyberattack that has resulted in data theft affecting oncology and multispecialty customers, creating potential legal, operational, and reputational risks that could impact future earnings.
  • Corporate insiders have been net sellers recently, with CEO Brian Tyler selling 8,463 shares in July 2026 and Director Bradley Lerman selling 301 shares in August 2026, which may signal a lack of confidence in the stock's near-term performance.
  • The company's negative return on equity of 253.21% in the most recent quarter, despite positive net margins, suggests significant leverage or accounting complexities that may concern value-focused investors regarding the efficiency of capital deployment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.45 billion
P/E Ratio
23.05
Consensus Rating
Moderate Buy
Consensus Price Target
$973.44 (+13.0% Upside)
Volume
183,741 shares
Average Volume
940,117 shares
Today's Range
$847.30
▼
$866.19
50-Day Range
$813.95
▼
$927.16
52-Week Range
$723.68
▼
$999.00
Dividend Yield
0.43%
Sanofi stock logo

22. Sanofi NASDAQ:SNY

$41.26 +0.52 (+1.26%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi is actively broadening its business development strategy to mitigate future risks, with new leadership describing the company as "phase agnostic" in its search for external opportunities. This means the firm is no longer limited to early-stage assets but is now evaluating deals across all development stages, including late-stage programs, to ensure strategic fit and financial return. This approach allows Sanofi to potentially acquire established products that can immediately contribute to revenue, helping to offset the upcoming loss of exclusivity for its flagship drug, Dupixent, in the early part of the next decade.
  • The company is undergoing a significant strategic review of its late-stage pipeline under new Chief Scientific Officer Mike Quigley, who has emphasized a mindset of "quicker decision-making, transparency, and underpromise, overdeliver." This rigorous assessment of scientific rigor and capital allocation aims to streamline the research and development process, potentially reducing the time to market for new therapies and improving the overall efficiency of the company's innovation engine, which is a key driver for long-term shareholder value.
  • Sanofi has secured a new strategic partnership with Cheplapharm, acquiring a 26.4% stake in the company to strengthen its position in mature medicines. This move is significant because it provides Sanofi with a robust distribution and commercialization platform for its established products, ensuring continued market presence and revenue stability even as the company focuses its R&D resources on next-generation therapies and specialty care areas like immunology and rare diseases.

Cons of Sanofi

  • Sanofi faces significant headwinds from the upcoming loss of exclusivity for Dupixent, its most profitable drug, in the early part of the next decade. This event is expected to erode a substantial portion of the company's revenue, and while management is working to mitigate this through new drug launches and acquisitions, the scale of the revenue loss poses a serious risk to future earnings growth and could pressure the stock price if the company fails to replace this revenue stream with equally profitable products.
  • The company has recently terminated several late-stage drug candidates, including amlitelimab, itepekimab, and belantamab, which signals a challenging environment for its R&D pipeline. These terminations not only represent a loss of potential future revenue but also raise questions about the scientific rigor and success rate of Sanofi's drug development process. Investors may be concerned that further pipeline setbacks could undermine the company's ability to deliver new growth drivers in the near term.
  • Sanofi's stock has been trading at or near its 52-week low, with a recent close of $41.11, indicating persistent downward pressure from the market. This sustained decline suggests that investors are skeptical about the company's ability to execute its strategic plans and generate future growth. The stock's position near its 52-week low also reflects a lack of confidence in the company's near-term prospects, which could deter new investors and limit upside potential in the short term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.02 billion
P/E Ratio
21.60
Consensus Rating
Hold
Consensus Price Target
$49.50 (+20.0% Upside)
Volume
2.58 million shares
Average Volume
3.38 million shares
Today's Range
$40.96
▼
$41.38
50-Day Range
$40.74
▼
$46.02
52-Week Range
$40.40
▼
$52.68
Dividend Yield
4.29%
GSK stock logo

23. GSK NYSE:GSK

$48.62 -0.73 (-1.47%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc is aggressively expanding its oncology pipeline through recent high-value acquisitions, including a deal with HUTCHMED for HMPL-A830 and a $750 million acquisition of a trispecific T-cell engager from Chimagen Biosciences, which signals a strong strategic pivot toward high-growth cancer treatments under CEO Luke Miels.
  • The company recently increased its quarterly dividend to $0.4515 per share, representing an annualized yield of approximately 3.6%, which provides a reliable income stream for investors and reflects management's confidence in maintaining cash flow despite significant R&D investments.
  • GSK plc demonstrated strong financial performance in its most recent reported quarter, beating consensus estimates with an EPS of $1.36 and revenue of $11.14 billion, while maintaining a high return on equity of 43.23%, indicating efficient capital deployment and robust profitability.

Cons of GSK

  • The consensus rating from eleven brokerages covering the company remains "Hold," with two analysts issuing sell ratings, indicating that the broader market is cautious about the stock's valuation and growth prospects despite recent positive news.
  • Recent labor advocacy efforts to preserve jobs at GSK's Dresden vaccine plant in Germany highlight potential workforce and restructuring concerns, which could lead to execution costs or reputational pressure that may impact operational stability.
  • The company's debt-to-equity ratio stands at 0.81, and its current ratio is 0.82, suggesting that GSK plc may face liquidity challenges or higher financial leverage risks as it funds its aggressive acquisition strategy and R&D pipeline.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.35 billion
P/E Ratio
15.20
Consensus Rating
Hold
Consensus Price Target
$56.50 (+16.2% Upside)
Volume
3.83 million shares
Average Volume
4.34 million shares
Today's Range
$48.52
▼
$49.05
50-Day Range
$48.14
▼
$53.78
52-Week Range
$42.85
▼
$61.69
Dividend Yield
3.61%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$429.35 -2.28 (-0.53%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The stock is currently trading at $435.18, which is below the average analyst price target of $463.70, suggesting potential upside as the consensus rating remains a Moderate Buy from twenty-three ratings firms.
  • HCA Healthcare, Inc. recently reported strong financial performance with 8.7% year-over-year revenue growth and earnings per share of $7.59, which exceeded the consensus estimate of $7.56, demonstrating the company's ability to drive volume growth and manage costs effectively.
  • The company is actively expanding its outpatient network, with a goal to reach 20 outpatient facilities per hospital by 2030, a strategic shift that positions the firm to capture more high-margin care outside of traditional inpatient settings.

Cons of HCA Healthcare

  • Legal and regulatory risks are increasing, as evidenced by a recent investigation by Pomerantz Law Firm on behalf of investors and an antitrust lawsuit against the company that has hit a roadblock, creating potential for future liabilities and reputational damage.
  • Short interest in the stock has been rising, with shares shorted increasing to approximately 6.48 million shares as of September 15, 2026, indicating that a growing number of traders are betting against the stock's future performance.
  • The company faces pressure from a changing service mix, where payer-mix dynamics may squeeze margins despite healthy volume growth, as the shift toward more complex or lower-reimbursed care types can impact overall profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.95 billion
P/E Ratio
14.37
Consensus Rating
Moderate Buy
Consensus Price Target
$463.70 (+8.0% Upside)
Volume
404,558 shares
Average Volume
1.35 million shares
Today's Range
$427.01
▼
$434.07
50-Day Range
$372.58
▼
$438.14
52-Week Range
$353.99
▼
$556.52
Dividend Yield
0.72%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$392.26 -0.47 (-0.12%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$85.07 billion
P/E Ratio
17.43
Consensus Rating
Moderate Buy
Consensus Price Target
$440.90 (+12.4% Upside)
Volume
469,742 shares
Average Volume
1.62 million shares
Today's Range
$386.75
▼
$396.14
50-Day Range
$375.44
▼
$424.78
52-Week Range
$274.84
▼
$436.24
Dividend Yield
1.74%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$759.76 +9.25 (+1.23%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. recently delivered a significant earnings beat in its most recent quarter, reporting actual earnings per share of $14.29 against a consensus estimate of $10.16, while also exceeding revenue expectations with $4.29 billion in sales compared to the $3.82 billion consensus, demonstrating strong fundamental performance that supports the current stock price of $752.25.
  • The company's EYLEA HD product is gaining substantial market momentum, representing roughly 60% of the EYLEA franchise net sales in the second quarter and becoming the only innovative brand in its category to gain market share, driven by label enhancements that allow for every-four-week dosing flexibility and new indications.
  • Regeneron Pharmaceuticals, Inc. is benefiting from the repayment of its Sanofi development balance, which is expected to lift earnings from the collaboration beginning in the third quarter, while Dupixent continues to annualize at roughly $24 billion in sales with more than 40% of total prescriptions now coming from indications outside of atopic dermatitis.

Cons of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. faces immediate competitive pressure in its core ophthalmology business, as rival Kodiak Sciences recently released positive Phase 3 data for its eye drugs that are on par with Regeneron's Eylea, causing Regeneron's stock to drop $35.79 to $752.25 on the news and raising concerns about future market share erosion.
  • The company is preparing for eventual biosimilar competition in the 2-milligram EYLEA market and for Keytruda in the oncology space, which could limit the growth potential of Libtayo and EYLEA as these competitors enter the market, despite Regeneron's current leadership in new-to-brand share for lung cancer.
  • There is inherent risk in the company's pipeline, particularly regarding the systemic approach to geographic atrophy, where executives have cautioned that historical attempts have been challenging and there are potential infection risks associated with extensive complement inhibition in an elderly population, which could lead to failed data readouts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.18 billion
P/E Ratio
18.77
Consensus Rating
Moderate Buy
Consensus Price Target
$802.18 (+5.6% Upside)
Volume
299,843 shares
Average Volume
827,600 shares
Today's Range
$742.94
▼
$758.27
50-Day Range
$651.18
▼
$852.03
52-Week Range
$541.00
▼
$859.34
Dividend Yield
0.50%
Moderna stock logo

27. Moderna NASDAQ:MRNA

$191.61 -11.85 (-5.82%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • Moderna, Inc. recently achieved a significant clinical milestone with its personalized cancer vaccine, intismeran autogene, which met its primary endpoint in the Phase 3 INTerpath-001 trial for melanoma when used in combination with Keytruda, validating the company's oncology pipeline and expanding its therapeutic reach beyond infectious diseases.
  • The stock is currently trading at $203.46, a substantial increase from its 52-week low of $22.28, reflecting strong market momentum and investor confidence in the company's recent strategic shifts and clinical successes.
  • Moderna, Inc. has entered high-level investment talks with the UAE government regarding advanced pharmaceutical manufacturing and R&D collaboration, signaling a strategic expansion into Middle Eastern healthcare markets and potential access to new capital and production capabilities.

Cons of Moderna

  • Moderna, Inc. continues to report negative earnings per share, with an actual EPS of -1.97 in the most recent quarter, indicating that the company is still operating at a loss and has not yet achieved profitability, which is a key concern for value-oriented investors.
  • The company faces ongoing legal challenges, including a recent loss in a bid to escape a US mRNA patent lawsuit filed by Bayer, which could result in significant financial liabilities or restrictions on its technology use.
  • Insider selling activity remains high, with President Stephen Hoge selling over 80,000 shares in September 2026 and CFO James M Mock selling nearly 35,000 shares, which may signal that company executives are taking advantage of the recent stock price surge to reduce their personal exposure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.39 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$77.83 (-59.4% Downside)
Volume
14.34 million shares
Average Volume
11.89 million shares
Today's Range
$184.58
▼
$196.83
50-Day Range
$53.86
▼
$203.46
52-Week Range
$22.28
▼
$208.90
Dividend Yield
N/A
Cigna Group stock logo

28. Cigna Group NYSE:CI

$272.99 -2.27 (-0.82%)
As of 02:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently announced an exclusive agreement with UnitedHealthcare Global, a significant strategic move that could expand its international health benefits footprint and drive future revenue growth in the global market.
  • With the current stock price at $274.94, the company offers a compelling valuation with a P/E ratio of 11.38, which is significantly lower than the broader market average, suggesting the stock may be undervalued relative to its earnings potential.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $7.78, which beat analyst consensus estimates of $7.60, while also achieving a return on equity of 19.75%, indicating efficient use of shareholder capital.

Cons of Cigna Group

  • Insider selling activity has been notable recently, with CEO David Cordani selling 201,878 shares in May 2026 and other insiders like Nicole S. Jones and Everett Neville also reducing their holdings, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • The company faces regulatory and reputational risks, as highlighted by recent reports alleging that The Cigna Group ran the clock on a teen's mental health claims, which could lead to increased scrutiny, potential legal costs, or damage to its brand reputation in the behavioral health sector.
  • Short interest in the stock has been increasing, with shares shorted rising to 6,562,998 as of September 15, 2026, representing a 4.59% month-over-month increase, indicating that a growing number of traders are betting against the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.14 billion
P/E Ratio
11.29
Consensus Rating
Moderate Buy
Consensus Price Target
$337.10 (+23.5% Upside)
Volume
1.70 million shares
Average Volume
1.68 million shares
Today's Range
$263.36
▼
$278.88
50-Day Range
$265.54
▼
$301.79
52-Week Range
$239.51
▼
$315.47
Dividend Yield
2.30%
Boston Scientific stock logo

29. Boston Scientific NYSE:BSX

$43.64 -0.24 (-0.54%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The stock is trading at a significant discount to its historical valuation, currently priced at $43.88, which is near its 52-week low of $42.20. This price represents a substantial drop from its 52-week high of $105.65, suggesting that the market may be overreacting to recent negative news, potentially creating a deep value opportunity for long-term investors who believe in the company's underlying fundamentals.
  • Boston Scientific Co. has demonstrated strong recent financial performance, reporting Q2 2026 earnings per share of $0.86, which exceeded the consensus estimate of $0.83. Additionally, the company reported revenue of $5.44 billion for the quarter, surpassing the consensus estimate of $5.38 billion, with year-over-year revenue growth of 7.5%, indicating that the business is still generating robust sales despite broader market pressures.
  • There is significant insider confidence in the company's future, as CEO Michael F. Mahoney purchased 186,240 shares at an average price of $48.33 in August 2026. This transaction, valued at approximately $9 million, represents a 13.27% increase in his ownership stake, signaling that company leadership believes the current stock price is undervalued relative to its intrinsic worth.

Cons of Boston Scientific

  • The stock has experienced a severe decline, losing more than half of its value from its 52-week high of $105.65 to the current price of $43.88. This significant drop reflects deep market skepticism about the company's future earnings power, and the stock is currently trading below its 50-day simple moving average of $46.96 and its 200-day simple moving average of $52.81, indicating a strong downward trend that may persist.
  • Recent analyst actions have been negative, with Citi downgrading the stock due to increasing competition and the fallout from a cyberattack. Additionally, Boston Scientific Co. was added to the Zacks Rank #5 (Strong Sell) list in September 2026, reflecting a consensus view that the company's near-term outlook is weak and that it may underperform its peers in the healthcare equipment sector.
  • Short interest in the stock has expanded significantly, with shares shorted increasing by 74.4% in August to reach 48,173,758 shares. This high level of short selling indicates that a substantial portion of the market is betting against the stock, and the days-to-cover ratio of 2.35 suggests that it would take over two days of average trading volume to cover all short positions, which can lead to increased volatility and downward pressure on the price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.25 billion
P/E Ratio
17.67
Consensus Rating
Moderate Buy
Consensus Price Target
$70.19 (+60.8% Upside)
Volume
8.76 million shares
Average Volume
18.74 million shares
Today's Range
$43.30
▼
$43.97
50-Day Range
$43.00
▼
$52.02
52-Week Range
$42.20
▼
$105.65
Dividend Yield
N/A
Natera stock logo

30. Natera NASDAQ:NTRA

$424.64 +10.12 (+2.44%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$61.23 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$336.07 (-20.9% Downside)
Volume
817,294 shares
Average Volume
1.38 million shares
Today's Range
$414.22
▼
$427.47
50-Day Range
$252.22
▼
$414.52
52-Week Range
$157.43
▼
$427.47
Dividend Yield
N/A
argenex stock logo

31. argenex NASDAQ:ARGX

$963.84 -6.83 (-0.70%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • argenx SE recently reported strong second-quarter financial results, with earnings per share of $7.32 significantly exceeding the consensus estimate of $5.86, while revenue of $1.54 billion also surpassed analyst expectations of $1.45 billion, demonstrating robust commercial execution and profitability with a net margin of 32.19%.
  • The stock is currently trading at $959.49, which is below the consensus price target of $1,158.61, suggesting potential upside of approximately 21% as analysts maintain a "Moderate Buy" consensus rating based on the company's strong sales momentum and upcoming clinical data readouts.
  • argenx SE has received recent positive analyst actions, including UBS Group raising its rating from "neutral" to "buy" with a price target of $1,400.00 and Wells Fargo & Company increasing its target to $1,415.00, reflecting confidence in the company's long-term growth trajectory and product franchise strength.

Cons of argenex

  • argenx SE was recently downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, suggesting that some analysts believe the stock's current valuation may not offer sufficient upside potential relative to its risks at this time.
  • The company's price-to-earnings ratio stands at 36.85, which is relatively high compared to broader market averages, indicating that the stock is priced for continued high growth and may be vulnerable to any disappointment in future earnings or revenue performance.
  • Short interest in the stock has been increasing recently, with shares shorted rising to 1,313,174 as of the September 15, 2026 record date, representing a month-to-month increase of 4.27%, which suggests that some market participants are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.30 billion
P/E Ratio
37.01
Consensus Rating
Moderate Buy
Consensus Price Target
$1,158.61 (+20.2% Upside)
Volume
167,111 shares
Average Volume
334,155 shares
Today's Range
$952.27
▼
$970.27
50-Day Range
$830.79
▼
$1,058.90
52-Week Range
$661.85
▼
$1,072.75
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$18.34 -0.17 (-0.89%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, posting earnings per share of $0.95 against a consensus estimate of $0.41, which signals robust profitability and operational efficiency to the market.
  • The company has secured a significant strategic partnership with Dr. Reddy's to distribute its Qdenga dengue vaccine in India, marking the launch of the country's first dengue vaccine and positioning Takeda Pharmaceutical Company Limited to capture a substantial new revenue stream in a high-growth emerging market.
  • Investors can benefit from the company's recent regulatory milestones, including the U.S. FDA accepting a new drug application for zasocitinib under priority review for moderate-to-severe plaque psoriasis, which offers a potential new therapeutic option and future revenue driver in the dermatology space.

Cons of Takeda Pharmaceutical

  • There is a notable discrepancy between the company's full-year 2026 earnings guidance of $3.009 per share and the sell-side analyst consensus of $1.54, suggesting that the company's internal targets may be overly optimistic or that analysts are skeptical of the sustainability of recent earnings beats.
  • Recent insider activity indicates potential lack of confidence among company leadership, as multiple insiders, including CEO Julie Kim and other executives, sold significant blocks of shares in August and September 2026, with one insider reducing their position by over 15% in a single transaction.
  • Takeda Pharmaceutical Company Limited carries a high valuation with a P/E ratio of 54.37, which is significantly elevated compared to many peers in the pharmaceutical sector, leaving little margin for error if future earnings growth does not meet the high expectations embedded in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.78 billion
P/E Ratio
53.96
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.19 million shares
Average Volume
3.02 million shares
Today's Range
$18.33
▼
$18.46
50-Day Range
$16.58
▼
$19.06
52-Week Range
$12.99
▼
$19.10
Dividend Yield
2.55%
Cencora stock logo

33. Cencora NYSE:COR

$303.69 -3.91 (-1.27%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • Cencora, Inc. recently raised its full-year adjusted earnings per share (EPS) outlook to a range of $17.75 to $17.95, signaling management confidence in the company's ability to generate profits above the previous consensus estimate of $17.85. This upward revision, combined with a $1 billion share repurchase program, suggests that the company believes its stock is undervalued and is committed to returning capital to shareholders, which can support the share price and enhance returns for investors.
  • The company reported strong third-quarter results with revenue of $84.75 billion, exceeding analyst estimates of $84.31 billion, and adjusted EPS of $4.48, which beat the consensus of $4.35. This performance demonstrates Cencora's ability to drive top-line growth of 5.1% year-over-year while maintaining profitability, indicating that its core pharmaceutical distribution business is resilient and capable of outperforming market expectations even in a challenging economic environment.
  • Executives have highlighted that the company's specialty-focused strategy is fueling growth into fiscal 2027, with specific momentum in high-demand areas such as oncology and retina care. This strategic pivot toward higher-margin specialty pharmaceuticals and expanded physician-services capabilities provides a durable growth engine that differentiates Cencora from generic distributors and supports long-term earnings expansion, as evidenced by the company's 125.45% return on equity in the most recent quarter.

Cons of Cencora

  • Cencora carries a high debt-to-equity ratio of 3.53, indicating that the company relies heavily on borrowed funds to finance its operations and growth. While this leverage can amplify returns in good times, it also increases financial risk and interest expense obligations, which could squeeze margins if interest rates remain elevated or if revenue growth slows, making the company more vulnerable to economic downturns compared to peers with lower leverage.
  • The stock has experienced significant volatility, hitting a 52-week low of $244.82 in May 2026 and a high of $377.54 in November 2025, reflecting a wide trading range that exposes investors to substantial drawdowns. This volatility, coupled with recent gap-down moves following earnings reports, suggests that the market is sensitive to any disappointment in execution or guidance, and investors may face significant short-term losses if the stock continues to trade near its lower bounds.
  • Recent insider activity includes notable share sales, such as EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026. While insider sales can be part of routine financial planning, a pattern of selling by key executives may signal a lack of confidence in the stock's near-term upside or a desire to diversify personal holdings, which could weigh on investor sentiment and limit the stock's ability to sustain gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.95 billion
P/E Ratio
22.56
Consensus Rating
Moderate Buy
Consensus Price Target
$370.85 (+22.1% Upside)
Volume
690,018 shares
Average Volume
1.49 million shares
Today's Range
$295.01
▼
$306.40
50-Day Range
$300.90
▼
$336.98
52-Week Range
$244.82
▼
$377.54
Dividend Yield
0.78%
Cardinal Health stock logo

34. Cardinal Health NYSE:CAH

$225.04 +1.13 (+0.50%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. recently reported strong earnings results on August 11, 2026, beating analyst expectations with an EPS of $2.91 compared to the consensus estimate of $2.42, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
  • The stock currently trades at $220.12, which is below the average analyst price target of $266.56, suggesting significant upside potential as the consensus rating remains a Moderate Buy with 16 analysts issuing Buy ratings versus only three Hold ratings.
  • Management has set fiscal 2027 guidance for EPS between $12.40 and $12.60, which exceeds the consensus estimate of $12.05, indicating that the company expects continued double-digit earnings growth across its five operating segments as specialty momentum builds.

Cons of Cardinal Health

  • Corporate insiders have been selling shares recently, with CEO Deborah Weitzman selling 7,354 shares and CAO Mary C. Scherer selling 2,302 shares in August 2026, which may signal that company leadership is taking advantage of higher stock prices to reduce their personal exposure.
  • The company's net margin is only 0.67% and it reported a negative return on equity of 98.53% in the most recent quarter, indicating that while revenue is growing, the company is struggling to convert that top-line growth into substantial bottom-line profitability and efficient use of shareholder capital.
  • Cardinal Health, Inc. faces regulatory risks from Inflation Reduction Act (IRA) pricing changes, which management expects will pressure pharmaceutical revenues, potentially impacting the company's ability to maintain its current margin levels despite efforts to protect profitability through distribution agreements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.11 billion
P/E Ratio
31.13
Consensus Rating
Moderate Buy
Consensus Price Target
$266.56 (+18.5% Upside)
Volume
737,904 shares
Average Volume
1.98 million shares
Today's Range
$222.07
▼
$226.49
50-Day Range
$220.12
▼
$248.88
52-Week Range
$150.77
▼
$258.30
Dividend Yield
0.94%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$86.38 -1.71 (-1.94%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company recently reported strong financial performance, beating analyst expectations with earnings per share of $0.78 compared to a consensus estimate of $0.74, while revenue of $1.74 billion exceeded the projected $1.70 billion, demonstrating robust demand for its structural heart disease therapies.
  • Edwards Lifesciences Co. is positioned to benefit from expanded Medicare coverage for transcatheter aortic valve replacement, which is expected to enable 100 to 200 additional U.S. centers to perform these procedures, significantly broadening the addressable market for its core SAPIEN platform.
  • The stock currently trades at $88.07, which is below the average analyst target price of $100.27, suggesting potential upside of approximately 13.8% as the twenty-three analysts covering the firm maintain a "Moderate Buy" consensus rating.

Cons of Edwards Lifesciences

  • The company's valuation is relatively high, with a price-to-earnings ratio of 50.61, which may limit upside potential if future earnings growth does not accelerate to justify the premium multiple compared to broader market averages.
  • Recent insider activity has been predominantly negative, with executives such as VP Annette Brüls and SVP Andrew M. Dahl selling thousands of shares in late August 2026, which some investors may interpret as a lack of confidence in the current stock price.
  • Wall Street Zen recently downgraded the stock from a "buy" to a "hold" rating, reflecting a more cautious outlook on the company's near-term performance and valuation relative to its peers in the healthcare equipment sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.73 billion
P/E Ratio
49.64
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+16.1% Upside)
Volume
2.03 million shares
Average Volume
4.53 million shares
Today's Range
$85.72
▼
$87.49
50-Day Range
$82.67
▼
$93.59
52-Week Range
$72.30
▼
$96.29
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

36. Becton, Dickinson and Company NYSE:BDX

$180.32 -1.65 (-0.91%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Becton, Dickinson and Company recently reported strong financial performance for the quarter ended August 6, 2026, beating analyst expectations with earnings per share of $3.23 compared to a consensus estimate of $3.14, while also exceeding revenue forecasts with $4.98 billion in sales against an expected $4.89 billion, demonstrating robust demand for its medical technology products.
  • The company maintains a low beta of 0.21, indicating that its stock price is significantly less volatile than the broader market, which can provide a defensive characteristic for investors seeking stability in their portfolios during periods of economic uncertainty.
  • With a current stock price of $182.03, Becton, Dickinson and Company offers a dividend yield of 2.28%, providing a steady income stream for investors, supported by a recent quarterly dividend announcement of $1.05 per share payable on September 30, 2026.

Cons of Becton, Dickinson and Company

  • The stock currently trades at a price-to-earnings ratio of 54.83, which is significantly higher than the market average, suggesting that the stock may be overvalued relative to its current earnings, and the consensus rating from analysts is a "Hold" with a price target of $187.67, indicating limited upside potential.
  • Insider selling activity has been notable, with executives such as CEO Thomas E Polen Jr. and EVP Michael Feld selling shares in recent months, including a sale of 4,152 shares by the CEO in August 2026, which may signal a lack of confidence from company leadership in the stock's near-term performance.
  • Short interest in Becton, Dickinson and Company has increased, with 11,316,237 shares shorted as of September 15, 2026, representing a 6.03% increase from the previous month, indicating that some investors are betting against the stock's price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.69 billion
P/E Ratio
54.31
Consensus Rating
Hold
Consensus Price Target
$187.67 (+4.1% Upside)
Volume
550,012 shares
Average Volume
2.52 million shares
Today's Range
$179.63
▼
$182.34
50-Day Range
$153.17
▼
$191.95
52-Week Range
$127.59
▼
$193.07
Dividend Yield
2.28%
Agilent Technologies stock logo

37. Agilent Technologies NYSE:A

$174.42 -0.61 (-0.35%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported third-quarter fiscal 2026 earnings that exceeded analyst expectations, posting $1.62 in earnings per share against a consensus estimate of $1.49, which demonstrates strong operational execution and profitability that can drive shareholder value.
  • The company has raised its full-year fiscal 2026 guidance, projecting earnings per share between $6.18 and $6.21, which is above the previous consensus estimate of $6.06, signaling management confidence in sustained revenue growth and margin expansion for the remainder of the year.
  • Agilent Technologies, Inc. continues to innovate in the life sciences sector by launching the Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers, a recent development that enhances its product portfolio and positions the company to capture demand for advanced, AI-driven laboratory automation solutions.

Cons of Agilent Technologies

  • The current stock price of $175.10 is above the average analyst price target of $170.33, suggesting that the stock may be overvalued relative to sell-side expectations, which could limit near-term upside potential or lead to a price correction.
  • Agilent Technologies, Inc. trades at a price-to-earnings ratio of 34.47, which is relatively high compared to many industrial and technology peers, indicating that investors are paying a premium for growth that may not be fully justified if earnings growth slows in the coming quarters.
  • Recent insider activity includes the sale of 634 shares by Director Mikael Dolsten in September 2026, which, while a small transaction, may signal a lack of confidence from company insiders or a desire to diversify personal holdings at current elevated price levels.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.17 billion
P/E Ratio
34.34
Consensus Rating
Moderate Buy
Consensus Price Target
$170.33 (-2.3% Downside)
Volume
853,377 shares
Average Volume
2.27 million shares
Today's Range
$173.13
▼
$176.04
50-Day Range
$133.49
▼
$175.42
52-Week Range
$108.35
▼
$177.05
Dividend Yield
0.59%
Teva Pharmaceutical Industries stock logo

38. Teva Pharmaceutical Industries NYSE:TEVA

$39.90 +0.09 (+0.23%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$46.50 billion
P/E Ratio
66.50
Consensus Rating
Moderate Buy
Consensus Price Target
$43.73 (+9.6% Upside)
Volume
1.99 million shares
Average Volume
6.81 million shares
Today's Range
$39.22
▼
$40.28
50-Day Range
$30.19
▼
$40.18
52-Week Range
$18.83
▼
$40.79
Dividend Yield
N/A
Medline stock logo

39. Medline NASDAQ:MDLN

$35.20 +0.22 (+0.61%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$46.28 billion
P/E Ratio
44.56
Consensus Rating
Moderate Buy
Consensus Price Target
$46.88 (+33.2% Upside)
Volume
3.43 million shares
Average Volume
7.43 million shares
Today's Range
$34.47
▼
$35.75
50-Day Range
$31.64
▼
$42.04
52-Week Range
$31.49
▼
$50.88
Dividend Yield
N/A
Veeva Systems stock logo

40. Veeva Systems NYSE:VEEV

$285.53 +6.96 (+2.50%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. recently launched the Veeva Study Builder Agent, an AI-powered tool that configures clinical study systems directly from a protocol, potentially reducing manual setup work and enabling studies to be configured in as little as one day, which could significantly improve operational efficiency and customer value.
  • The company secured major new customer wins, including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM, which expands its presence with large biopharmaceutical customers and supports recurring revenue and cross-selling opportunities.
  • Veeva Systems Inc. reported strong quarterly earnings on August 26, 2026, with earnings per share of $2.35, beating analysts' consensus estimates of $2.23, and revenue of $927.96 million, exceeding expectations of $905.38 million, demonstrating robust financial performance and execution.

Cons of Veeva Systems

  • Wall Street Zen recently downgraded Veeva Systems Inc. from a "buy" rating to a "hold" rating, indicating that some analysts believe the stock's upside potential has waned despite excellent execution.
  • The stock has declined 2.6% since its latest earnings report, suggesting that investors may be seeking stronger forward guidance or additional evidence that AI investments will accelerate results, and the premium valuation increases sensitivity to estimates and execution.
  • Insider activity shows significant selling, with Director Priscilla Hung selling 750 shares on September 9, 2026, and insider Thomas Schwenger selling 36,000 shares on August 13, 2026, representing a 64.92% decrease in his position, which could signal reduced confidence from company insiders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.23 billion
P/E Ratio
46.96
Consensus Rating
Moderate Buy
Consensus Price Target
$284.88 (-0.2% Downside)
Volume
668,035 shares
Average Volume
2.38 million shares
Today's Range
$275.70
▼
$288.41
50-Day Range
$179.36
▼
$285.56
52-Week Range
$148.05
▼
$310.50
Dividend Yield
N/A
Humana stock logo

41. Humana NYSE:HUM

$384.25 -2.62 (-0.68%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, posting earnings per share of $7.61 against a consensus estimate of $7.27, while also exceeding revenue forecasts with $40.89 billion in sales, a 26.2% increase year-over-year.
  • The stock has experienced significant momentum, with shares trading at $389.91 as of September 28, 2026, reflecting a substantial recovery from its 52-week low of $163.11 and approaching its 52-week high of $428.88, indicating strong market confidence in the company's trajectory.
  • Recent analyst actions have been positive, including an upgrade from Barclays to an "Overweight" rating with a price target of $515, and a "Buy" rating from Wall Street Zen, suggesting that institutional investors see significant upside potential in the stock.

Cons of Humana

  • The consensus rating from thirty ratings firms is currently "Hold" with an average price target of $403.91, which is only slightly above the current stock price of $389.91, suggesting limited near-term upside potential for investors entering at current levels.
  • Humana Inc. faces regulatory and reputational risks, as evidenced by a federal watchdog accusing the company of upcoding in Medicare Advantage plans, which could lead to increased scrutiny, potential fines, or operational changes that impact profitability.
  • The company is undergoing significant operational changes, including dropping plans covering 600,000 members, which may lead to member dissatisfaction and potential churn, as the replacement plans are not identical and could result in higher costs or reduced benefits for enrollees.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.14 billion
P/E Ratio
36.35
Consensus Rating
Hold
Consensus Price Target
$408.61 (+6.3% Upside)
Volume
464,955 shares
Average Volume
1.65 million shares
Today's Range
$378.50
▼
$391.33
50-Day Range
$362.31
▼
$408.79
52-Week Range
$163.11
▼
$428.88
Dividend Yield
0.89%
IQVIA stock logo

42. IQVIA NYSE:IQV

$270.65 +1.66 (+0.62%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. recently reported strong second-quarter financial results, with earnings per share of $3.15 exceeding the consensus estimate of $3.03 and revenue of $4.37 billion surpassing the expected $4.30 billion, demonstrating the company's ability to outperform market expectations and drive shareholder value through robust operational performance.
  • The stock is currently trading at $268.88, which is near its 52-week high of $277.40, indicating strong recent momentum and investor confidence in the company's trajectory, particularly as it has significantly outperformed its 52-week low of $154.50 over the past year.
  • Analysts have shown increasing optimism, with Royal Bank of Canada recently raising its price target to $319.00 and assigning an "outperform" rating, citing a "meaningful" tailwind from accelerating new drug approvals that directly benefits IQVIA's clinical research and analytics services.

Cons of IQVIA

  • The stock is trading at a price-to-earnings ratio of 33.36, which is relatively high compared to many other sectors, suggesting that the stock may be overvalued relative to its current earnings and leaving little room for error if growth slows or market sentiment shifts.
  • Corporate insiders have been selling shares recently, with James G. Berkshire selling 2,668 shares and Keriann Cherofsky selling 558 shares in recent months, which can be interpreted as a lack of confidence from those with the most knowledge of the company's internal operations.
  • IQVIA Holdings Inc. has a debt-to-equity ratio of 2.18, indicating a significant level of leverage relative to its equity, which could increase financial risk and interest expenses, particularly if interest rates remain elevated or the company faces economic headwinds.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.55 billion
P/E Ratio
33.58
Consensus Rating
Moderate Buy
Consensus Price Target
$264.31 (-2.3% Downside)
Volume
601,447 shares
Average Volume
1.72 million shares
Today's Range
$267.61
▼
$273.16
50-Day Range
$198.96
▼
$275.38
52-Week Range
$154.50
▼
$277.40
Dividend Yield
N/A
Revolution Medicines stock logo

43. Revolution Medicines NASDAQ:RVMD

$206.75 +2.27 (+1.11%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$44.33 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$234.33 (+13.3% Upside)
Volume
903,791 shares
Average Volume
2.89 million shares
Today's Range
$203.00
▼
$209.79
50-Day Range
$180.92
▼
$221.15
52-Week Range
$45.60
▼
$224.31
Dividend Yield
N/A
Waters stock logo

44. Waters NYSE:WAT

$441.56 -1.70 (-0.38%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$43.38 billion
P/E Ratio
110.12
Consensus Rating
Moderate Buy
Consensus Price Target
$434.60 (-1.6% Downside)
Volume
274,411 shares
Average Volume
963,278 shares
Today's Range
$441.72
▼
$448.21
50-Day Range
$370.93
▼
$443.80
52-Week Range
$282.77
▼
$448.21
Dividend Yield
N/A
Illumina stock logo

45. Illumina NASDAQ:ILMN

$275.91 +3.91 (+1.44%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More about Illumina

Pros of Illumina

  • Illumina, Inc. recently reported strong financial performance for the quarter ended July 30, 2026, with earnings per share of $1.31, which beat the consensus estimate of $1.23, and revenue of $1.16 billion, exceeding the expected $1.13 billion, demonstrating the company's ability to outperform market expectations and drive shareholder value through robust operational execution.
  • The stock has experienced significant momentum, reaching a 52-week high of $277.95 and trading at a current price of $270.00 as of September 25, 2026, reflecting a year-to-date return of over 100% and indicating strong investor confidence in the company's growth trajectory and market position in the life sciences sector.
  • Illumina, Inc. has raised its full-year 2026 earnings per share guidance to a range of $5.30 to $5.40, signaling management's confidence in continued revenue growth and profitability, which supports the narrative of sustainable expansion in genomic analysis technologies and clinical adoption of its sequencing platforms.

Cons of Illumina

  • The stock trades at a price-to-earnings ratio of 53.18, which is significantly higher than the consensus price target of $199.12, suggesting that the current valuation may be stretched relative to analyst expectations and could be vulnerable to correction if growth does not continue to accelerate at the pace implied by the market price.
  • Insider selling has been substantial, with Director Keith Meister selling over 3 million shares in the past six months for an estimated $591 million, and other executives also reducing their positions, which may signal a lack of confidence from those with the most intimate knowledge of the company's internal operations and future prospects.
  • Short interest in Illumina, Inc. has increased to 10.58 million shares as of September 15, 2026, representing 7.22% of the float, indicating that a significant portion of the market is betting against the stock's future performance, which could lead to volatility and downward pressure if the bearish sentiment gains further traction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.70 billion
P/E Ratio
51.52
Consensus Rating
Hold
Consensus Price Target
$209.75 (-24.0% Downside)
Volume
1.64 million shares
Average Volume
2.14 million shares
Today's Range
$270.30
▼
$280.17
50-Day Range
$187.96
▼
$273.90
52-Week Range
$88.00
▼
$280.17
Dividend Yield
N/A
IDEXX Laboratories stock logo

46. IDEXX Laboratories NASDAQ:IDXX

$525.94 -7.50 (-1.41%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The stock is currently trading at $529.06, which is significantly below the consensus price target of $747.00 set by analysts who maintain a Moderate Buy rating, suggesting substantial potential for price appreciation as the market re-evaluates the company's valuation.
  • IDEXX Laboratories, Inc. recently acquired CoVetAI, a veterinary AI software firm, which expands the company's capabilities in workflow intelligence and diagnostics, positioning it to improve veterinary practice performance and capture new revenue streams through technology integration.
  • The company demonstrated strong financial performance in the most recent quarter, reporting earnings per share of $4.27, which exceeded the consensus estimate of $3.94, while revenue grew 9.7% year-over-year to $1.22 billion, indicating robust demand for its diagnostic products.

Cons of IDEXX Laboratories

  • The company faces headwinds from a decline in clinical veterinary visits, with management expecting approximately a 1.5% decline in visits during the second half of the year, which could pressure revenue growth despite efforts to increase diagnostic utilization per visit.
  • Recent insider activity shows significant selling, including a sale of 2,203 shares by Director Lawrence D. Kingsley in September 2026 and a larger sale of 23,326 shares by CEO Jonathan Jay Mazelsky in February 2026, which may signal reduced confidence from company leadership.
  • The stock has experienced a significant decline from its 52-week high of $769.98 to its current price of $529.06, reflecting a 26% slide that indicates substantial market skepticism and potential overvaluation concerns among investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.46 billion
P/E Ratio
37.01
Consensus Rating
Moderate Buy
Consensus Price Target
$747.00 (+42.0% Upside)
Volume
175,674 shares
Average Volume
570,089 shares
Today's Range
$522.60
▼
$531.11
50-Day Range
$504.70
▼
$595.76
52-Week Range
$500.61
▼
$769.98
Dividend Yield
N/A
BeOne Medicines stock logo

47. BeOne Medicines NASDAQ:ONC

$370.19 +4.92 (+1.35%)
As of 02:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$40.64 billion
P/E Ratio
65.17
Consensus Rating
Buy
Consensus Price Target
$402.71 (+8.8% Upside)
Volume
165,319 shares
Average Volume
304,026 shares
Today's Range
$370.00
▼
$376.50
50-Day Range
$313.77
▼
$376.86
52-Week Range
$253.95
▼
$385.22
Dividend Yield
N/A
Biogen stock logo

48. Biogen NASDAQ:BIIB

$227.88 +0.81 (+0.36%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently reported second-quarter earnings that significantly exceeded market expectations, posting earnings per share of $3.60 against a consensus estimate of $2.94, which demonstrates strong operational performance and profitability that can drive shareholder value.
  • The company's stock price reached a new 52-week high, trading at $227.07 as of September 29, 2026, reflecting a substantial upward trend from its 52-week low of $136.93 and indicating strong investor confidence in the company's future growth trajectory.
  • Biogen Inc. has secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, a development that enhances patient accessibility and convenience, potentially broadening the treatment reach and market adoption of this key therapy.

Cons of Biogen

  • Biogen Inc. carries a high price-to-earnings ratio of 40.19, which is significantly elevated compared to many peers, meaning investors are paying a premium for earnings that may not be sustainable if growth slows or if the company faces competitive pressures.
  • The company's full-year 2026 earnings guidance of $12.00 to $13.00 per share is below the consensus estimate of $13.45, indicating that management expects a deceleration in earnings growth relative to what the broader market currently anticipates.
  • Short interest in Biogen Inc. has increased, with shares shorted rising to 5,817,797 as of the September 15, 2026 record date, suggesting that a portion of the market is betting against the stock's future performance despite recent highs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.68 billion
P/E Ratio
40.34
Consensus Rating
Moderate Buy
Consensus Price Target
$230.14 (+1.0% Upside)
Volume
607,730 shares
Average Volume
1.20 million shares
Today's Range
$225.51
▼
$229.36
50-Day Range
$197.74
▼
$228.69
52-Week Range
$138.00
▼
$230.49
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

49. Alnylam Pharmaceuticals NASDAQ:ALNY

$251.35 -2.72 (-1.07%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. recently reported strong financial performance, with quarterly revenue of $1.29 billion, representing a 66.9% year-over-year increase, and earnings per share of $1.84, which exceeded analyst consensus estimates of $1.63, demonstrating robust commercial execution and profitability.
  • The company maintains a favorable balance sheet with a quick ratio of 2.99 and a current ratio of 3.05, indicating strong liquidity and the ability to meet short-term obligations, while a debt-to-equity ratio of 0.75 suggests a manageable level of leverage for a biopharmaceutical firm.
  • Analyst sentiment remains positive with a consensus rating of "Moderate Buy" from 23 research firms, and a recent price target of $455.00 from HC Wainwright implies significant upside potential from the current stock price of $255.96, reflecting confidence in the company's long-term growth trajectory.

Cons of Alnylam Pharmaceuticals

  • The current stock price of $255.96 is significantly below the 52-week high of $495.55, indicating a substantial decline in valuation over the past year, which may reflect ongoing market concerns about the company's growth prospects or competitive positioning.
  • Short interest has increased recently, with 7,194,097 shares shorted as of September 15, 2026, representing a 13.47% month-over-month increase, suggesting that a significant portion of the market is betting against the stock's future performance.
  • Several major financial institutions have recently lowered their price targets, including Morgan Stanley reducing its target from $400.00 to $300.00 and Citigroup lowering its target from $380.00 to $340.00, indicating a more cautious outlook on the company's near-term earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.66 billion
P/E Ratio
46.75
Consensus Rating
Moderate Buy
Consensus Price Target
$367.20 (+46.1% Upside)
Volume
307,156 shares
Average Volume
1.44 million shares
Today's Range
$250.00
▼
$254.44
50-Day Range
$205.48
▼
$288.41
52-Week Range
$197.81
▼
$495.55
Dividend Yield
N/A
Royalty Pharma stock logo

50. Royalty Pharma NASDAQ:RPRX

$58.50 +0.28 (+0.47%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The stock is currently trading at $58.37, which is below the consensus price target of $61.29 set by eight research analysts who have issued a "Buy" recommendation, suggesting potential upside for investors.
  • Royalty Pharma plc recently reported earnings per share of $1.32 for the quarter, which exceeded the consensus estimate of $1.27, demonstrating the company's ability to generate strong profits relative to analyst expectations.
  • The company maintains a low beta of 0.44, indicating that its stock price is less volatile than the overall market, which can provide a more stable investment experience during periods of market uncertainty.

Cons of Royalty Pharma

  • Recent insider activity has been predominantly selling, with EVP Christopher Hite selling 100,000 shares in September and other executives like Marshall Urist and Terrance P Coyne also reducing their positions over the past few months.
  • The company's revenue of $674.14 million in the latest quarter fell short of the analyst consensus estimate of $758.93 million, indicating potential challenges in meeting top-line growth expectations.
  • Wall Street Zen recently downgraded Royalty Pharma plc from a "strong-buy" rating to a "buy" rating, suggesting that some analysts believe the stock may be overvalued or face near-term headwinds.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.65 billion
P/E Ratio
40.36
Consensus Rating
Buy
Consensus Price Target
$61.29 (+4.8% Upside)
Volume
1.48 million shares
Average Volume
3.43 million shares
Today's Range
$57.70
▼
$58.64
50-Day Range
$56.77
▼
$63.96
52-Week Range
$35.23
▼
$64.38
Dividend Yield
1.61%